Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Exosome compound with tumor inhibition effect

A technology of tumor suppression and exosomes, which is applied in the field of biomedicine, can solve the problems of low progression and survival rate of recurrent and metastatic osteosarcoma, inability to effectively optimize the treatment plan and drugs, etc.

Pending Publication Date: 2022-07-01
厦门大学附属翔安医院 +1
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in the past few decades, the treatment of osteosarcoma has entered a bottleneck period, unable to effectively optimize the current treatment regimen or identify new therapeutic drugs, and the 5-year progression-free survival rate of recurrent and metastatic osteosarcoma is still below 30%.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Exosome compound with tumor inhibition effect
  • Exosome compound with tumor inhibition effect
  • Exosome compound with tumor inhibition effect

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0034] Example 1 Separation and extraction of exosomes and loading of drug rifampicin

[0035] (1) Isolation and extraction of exosomes from bone marrow mesenchymal stem cells (BMSCs): Select human BMSCs as the research object, use serum without exosomes for cell culture, and select ultracentrifugation to extract exosomes. The methods are as follows: Human Source BMSCs were incubated at 37 °C, 5% CO 2 In a cell incubator, collect 50 mL of cell supernatant at 300 g, centrifuge at 4 °C for 15 min, remove impurities and take the supernatant; 3000 g, centrifuge at 4 °C for 15 min, remove cell debris and take the supernatant; 20000 g, centrifuge at 4 °C for 60 min, take the supernatant Filter through a 0.22 μm sieve; centrifuge at 120,000 g for 120 min at 4°C, carefully remove the supernatant and place it upside down on filter paper to blot dry. , stored at 80°C for later use;

[0036] (2) Preparation of rifampicin-encapsulated exosomes: Add 10 mg / mL of rifampicin to the exosomes...

Embodiment 2

[0038] Example 2 Inhibitory effect of exosome complex on osteosarcoma 143B cell line in vitro

[0039] (1) Human osteosarcoma cell line 143B was inoculated in high glucose complete medium DMEM containing 10% FBS and 1% penicillin, and then placed in DMEM containing 5% CO. 2 cultured in a constant temperature incubator at 37°C. Set up blank control group (Control): add the same amount of PBS solution as other groups in the culture medium; no drug-loaded exosome group (EXO): the culture medium contains 10 6 exosomes / mL; exosome complex group (EXO-RIF): culture medium containing 25 μg / mL rifampicin and 10 6 exosomes / mL.

[0040] (2) Detect the activity of cells by CCK-8 experiment: resuspend the cells by centrifugation to make a cell suspension, then count the cell suspension, dilute the cells to 50 cells / μL, and inoculate 100 μL in a 96-well plate, 10 replicates were set for each group of cells. After culturing in medium containing different drugs for 24 h, 10 μL of CCK-8 rea...

Embodiment 3

[0046] Example 3 Tumor growth inhibition effect of exosome complex on tumor-bearing nude mice

[0047] In this example, 18 male BALB / C nude mice aged 4-6 weeks were selected, and each nude mouse was injected with 20 μL containing 10 7 A suspension of 143B osteosarcoma cells was randomly divided into 3 groups 7 days after tumor injection, with 6 cells in each group. Blank control group (Control): daily intravenous injection of the same amount of normal saline solution as other groups; no drug-loaded exosome group (EXO): daily intravenous injection containing 10 8 exosomes / mL saline solution; exosome complex group (EXO-RIF): According to the weight of nude mice, according to the dose of 10 mg / kg rifampicin, daily intravenous injection containing 10 mg / mL rifampicin and 10 mg / mL rifampicin 8 each / mL exosomes in saline solution. After 21 days of continuous injection, the samples were taken and weighed for observation.

[0048] like Figure 16 and Figure 17 As shown, the tumo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an exosome compound with a tumor inhibition effect. The exosome compound comprises exosomes of human mesenchymal stem cells and rifampicin. According to the invention, an exosome drug loading technology is utilized to load an antituberculous drug rifampicin into the human-derived mesenchymal stem cell exosome, and experiments find that the human-derived mesenchymal stem cell exosome has remarkable curative effects of inhibiting growth, proliferation, migration and invasion of tumors, can promote apoptosis and cell cycle arrest of the tumors, and can be used for preparing a medicine for treating the tumors. Particularly, the compound has an obvious growth inhibition effect on osteosarcoma cells. After being prepared into the tumor treatment medicine, the compound has important significance on improving the treatment effect of osteosarcoma patients, improving prognosis and increasing the survival rate.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to an exosome complex with tumor suppressing effect. Background technique [0002] Osteosarcoma is the most common primary bone malignancy in children and adolescents and the highest incidence of primary soft tissue malignancies. With the advancement of surgery and the establishment of new chemotherapy regimens, significant progress has been made in the diagnosis and treatment of osteosarcoma. However, in the past few decades, the treatment of osteosarcoma has entered a bottleneck period, and it is impossible to effectively optimize the current treatment plan or identify new therapeutic drugs, and the 5-year progression-free survival rate of recurrent and metastatic osteosarcoma is still less than 30%. Therefore, exploring new treatment options and developing new anti-osteosarcoma drugs is an urgent problem to be solved. SUMMARY OF THE INVENTION [0003] In order to solve th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/28A61K31/496A61K47/46A61P19/08A61P35/00
CPCA61K35/28A61K31/496A61K47/46A61P35/00A61P19/08A61K2300/00
Inventor 吉光荣陈文凯许韧李娜李宗光于乃春陈永杰龚枫清
Owner 厦门大学附属翔安医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com